1. Dual targeting of PTP1B and glucosidases with new bifunctional iminosugar inhibitors to address type 2 diabetes
- Author
-
Amelia Morrone, Paolo De Paoli, Francesca Cardona, Xhenti Ferhati, Andrea Goti, Camilla Matassini, Maria Giulia Fabbrini, and Antonio J. Moreno-Vargas
- Subjects
medicine.drug_class ,medicine.medical_treatment ,Molecular Conformation ,Iminosugar ,Type 2 diabetes ,Pharmacology ,01 natural sciences ,Biochemistry ,Structure-Activity Relationship ,Drug Discovery ,medicine ,Humans ,Hypoglycemic Agents ,Molecular Biology ,Protein kinase B ,Protein Tyrosine Phosphatase, Non-Receptor Type 1 ,chemistry.chemical_classification ,Alpha-glucosidase inhibitor ,type 2 diabetes, bifunctional compounds, alpha--glucosidase inhibitors, PTP1B inhibitors, iminosugars, insulin-mimetic activity ,Dose-Response Relationship, Drug ,biology ,010405 organic chemistry ,Insulin ,Organic Chemistry ,Hep G2 Cells ,medicine.disease ,Imino Sugars ,0104 chemical sciences ,010404 medicinal & biomolecular chemistry ,Enzyme ,Diabetes Mellitus, Type 2 ,chemistry ,biology.protein ,Phosphorylation ,Glucosidases - Abstract
The diffusion of type 2 diabetes (T2D) throughout the world represents one of the most important health problems of this century. Patients suffering from this disease can currently be treated with numerous oral anti-hyperglycaemic drugs, but none is capable of reproducing the physiological action of insulin and, in several cases, they induce severe side effects. Developing new anti-diabetic drugs remains one of the most urgent challenges of the pharmaceutical industry. Multi-target drugs could offer new therapeutic opportunities for the treatment of T2D, and the reported data on type 2 diabetic mice models indicate that these drugs could be more effective and have fewer side effects than mono-target drugs. α-Glucosidases and Protein Tyrosine Phosphatase 1B (PTP1B) are considered important targets for the treatment of T2D: the first digest oligo- and disaccharides in the gut, while the latter regulates the insulin-signaling pathway. With the aim of generating new drugs able to target both enzymes, we synthesized a series of bifunctional compounds bearing both a nitro aromatic group and an iminosugar moiety. The results of tests carried out both in vitro and in a cell-based model, show that these bifunctional compounds maintain activity on both target enzymes and, more importantly, show a good insulin-mimetic activity, increasing phosphorylation levels of Akt in the absence of insulin stimulation. These compounds could be used to develop a new generation of anti-hyperglycemic drugs useful for the treatment of patients affected by T2D.
- Published
- 2019
- Full Text
- View/download PDF